All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

June 7, 2024

Trends and Obstacles in the CGT Field (BIO 2024)

Author(s):

Feliza Mirasol

Lonza’s Joe Garrity and Jerry Jiang discuss the latest trends and challenges in commercializing new CGTs.

Cell and gene therapies (CGTs) remain an important focus in the biopharma industry. During BIO 2024, Joe Garrity, senior director and head of Autologous Cell Therapy, and Jerry Jiang, clinical application specialist, Personalized Medicine, Cell and Gene Therapy, both at Lonza, discuss the latest trends and hurdles in the CGT space.

“Moving from the 2017 timeframe into 2020, we saw a heavy focus on a [significant amount of] money floating around focusing on autologous cell therapies and how we can better provide these life changing therapies to patients,” Garrity says. From the autologous cell therapy perspective, efficacy has been achieved, but the challenge remains that an autologous cell therapy is one manufacturing batch, or one dose, per patient. “The scaling is a little bit of a challenge,” Garrity says, noting, “This is where the allogeneic approach has taken over, and in the cell therapy space, we've really seen that shift … seen [focus] go from two-thirds autologous to one-third allogeneic to almost a 50/50 split.”

Garrity expects this trend to continue to where the industry may see a rise in allogeneic cell therapies, from a molecule number standpoint. “We're seeing a [bigger] influx of allogeneic cell therapies trying to provide a secondary option to commercially viable CAR-T [chimeric antigen receptor T cell]/CAR-NK [chimeric antigen receptor natural killer cell] drug products,” he states.

“At the end of the day it’s really about providing access and availability of cell therapies to those who really need it,” Jiang adds. “The cell therapy production process can be complex, and current solutions are not sufficient to be able to scale to the patient demand. So, as a result, new technologies are being developed to help reduce timelines and cost and improve scalability.”

Another issue Jiang points out is the difficulty in finding technicians who are able to work with and produce these therapies. “We've seen [many] different manufacturers try to figure out different ways of scaling down … either making the process faster or taking out other aspects of their manufacturing process to really streamline this process, as well as just reducing the costs [of these] therapies.”

Click the video above for the full interview. BIO 2024 occurred on June 3–6 in San Diego, Calif.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Understanding the Operational Impacts of the 15% US-EU Pharma Tariff Cap
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
Advertisement
B. Braun - german medical technology company, Czech branch | Image Credit: © Solarisys - stock.adobe.com
August 23rd 2025

B. Braun Medical Voluntarily Recalls Two Injections, Citing Presence of Particulate Matter

Patrick Lavery
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 23rd 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 23rd 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 23rd 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results
August 23rd 2025

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Christopher Cole
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 23rd 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
Related Content
Advertisement
B. Braun - german medical technology company, Czech branch | Image Credit: © Solarisys - stock.adobe.com
August 23rd 2025

B. Braun Medical Voluntarily Recalls Two Injections, Citing Presence of Particulate Matter

Patrick Lavery
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 23rd 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 23rd 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 23rd 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results
August 23rd 2025

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Christopher Cole
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 23rd 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.